Lisata Therapeutics (NASDAQ:LSTA) Trading Up 2.3%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was up 2.3% during mid-day trading on Friday . The stock traded as high as $3.52 and last traded at $3.51. Approximately 6,429 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 14,796 shares. The stock had previously closed at $3.43.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a report on Friday, June 14th.

Lisata Therapeutics Price Performance

The stock has a market capitalization of $29.17 million, a PE ratio of -1.43 and a beta of 1.24. The business’s fifty day moving average price is $3.15 and its two-hundred day moving average price is $3.01.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. As a group, equities research analysts anticipate that Lisata Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC raised its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 5.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 284,669 shares of the company’s stock after purchasing an additional 14,830 shares during the quarter. Lisata Therapeutics accounts for approximately 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. BML Capital Management LLC owned 3.43% of Lisata Therapeutics worth $888,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.